Kondo T, Ezzat S, Asa SL.

Pathogenetic mechanisms in thyroid follicular-cell neoplasia.

Nat Rev Cancer 6:292-306 (2006)
DOI:10.1038/nrc1836

Li DD, Zhang YF, Xu HX, Zhang XP

The role of BRAF in the pathogenesis of thyroid carcinoma.

Front Biosci (Landmark Ed) 20:1068-78 (2015)
DOI:10.2741/4359

Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M, Richtig E

Beyond the BRAF(V)(600E) hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.

Br J Dermatol 177:936-944 (2017)
DOI:10.1111/bjd.15436

Guadarrama-Orozco JA, Ortega-Gomez A, Ruiz-Garcia EB, Astudillo-de la Vega H, Meneses-Garcia A, Lopez-Camarillo C

Braf V600E mutation in melanoma: translational current scenario.

Clin Transl Oncol 18:863-71 (2016)
DOI:10.1007/s12094-015-1469-6

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

N Engl J Med 366:707-14 (2012)
DOI:10.1056/NEJMoa1112302